Ana Popovic, general manager of Serbia’s generics association, Genezis, gives her thoughts on how the generics industry has progressed in the country, what room for improvement remains, and the impact of EU succession.
Where does Genezis stand in 2017 and what is keeping you busy at the moment?
"The Serbian market is a generic-dominated market, with the local manufacturers still enjoying a privileged status."
Branislav Kotlarik, Ferring’s general manager for the Balkans – whose remit includes Hungary, Romania and Bulgaria as well as all of ex-Yugoslavia – gives his insights into managing such a…
Gordana Zdravkovic has overseen the progression of BIOTEC International, Serbia through thick and thin. With over 25 years’ experience in the life sciences industry, she has put together a fantastic…
Nebojsa Skuljec has held various positions in MSD Healthcare across the Balkans before his promotion to country lead for Serbia and Balkans emerging markets 14 months ago. In this interview…
In a market environment that, up until recently, has been severely difficult for producers of chemical pharmaceutical products to operate in, three enterprising Serbian companies – Pharmanova, INNventa and Esensa…
Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared with 44 in Bulgaria and 27 in…
Serbia has had an undoubtedly troubled history since the breakup of Yugoslavia in the early 1990s. A costly war and ensuing UN sanctions have left the country’s economy a few…
See our Cookie Privacy Policy Here